SEBI Registration No - INA000003197 Investment in stock and commodity market are subject to market risk. Please do not trade on those tips which are not provided through SMS.



Cadila receives approval for Bumetanide, Strides receives approval for Cinacalcet HCL

Cadila has received approval for Bumetanide tablet in 0.5mg, 1mg and 2mg strengths. This is a generic equivalanet of Validus Pharma’s Bumex tablets. There are about six generic companies already in this drug, while Cadila will be the seventh generic drug supplier.

The Bumetanide tablet had US sales of ~$84.5mn for the 12-month period ending November, 2017 according to IMS Health.

The approval for Strides Shasun’s Cinacalcet HCL is for three strengths i.e. 30/60/90 mg. Cinacalcet HCL is sold under brand Sensipar by Amgen Inc. Sensipar generated $1.7bn global sales in 2017 for Amgen. The first patent (primary patent) on this drug had expired on March 08, 2018, two second patents are still remaining, which will expire in 2026. Indian companies Cipla, Aurobindo and Cadila have also received approval to make this drug in 2018.
Both the stocks are likely to remain in focus today.

Source url :